Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapyArmando Santoro, Alexia Bertuzzi, Alessandro Comandone et al.|Annals of Oncology|2012Cited by 54
Primary melanoma of the stomach treated by BRAF inhibitor and immunotherapyElena Bolzacchini, Graziella Pinotti, Ilaria Marcon et al.|Digestive and Liver Disease|2016Cited by 11
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)Massimo Aglietta, Paola Queirolo, Vanna Chiarion‐Sileni et al.|Targeted Oncology|2021Cited by 7
When primary hyperparathyroidism comes as good newsDaniela Gallo, Eliana Piantanida, Luigi Bartalena et al.|Endocrinology Diabetes and Metabolism Case Reports|2020Cited by 6
Outcomes in patients with <i>BRAF</i> <sup>V600</sup> –mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinibMassimo Aglietta, Paola Queirolo, Vanna Chiarion‐Sileni et al.|Tumori Journal|2023Cited by 4